Almonertinib, a new third-generation EGFR-TKI, was approved by the National Medical Products Administration as first-line treatment of locally advanced or metastatic NSCLC with 19Del and 21L858R mutation on 16 December 2021. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.